Delivery Order SPE2DB24D1205-SPE2DB25FDATJ
- Not listed
- The Defense Logistics Agency awarded a $1,501.90 delivery order to AmerisourceBergen Drug Corp for Gadavist 10 mmol/10 ml vials, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gadavist 10 mmol/10 mL vials with a ceiling value of $1,501.90. This non-competitive, firm fixed-price delivery order was awarded on September 5, 2025, with an ultimate completion date of September 8, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Gadavist is a contrast agent used in medical imaging procedures, reflecting the company's role as a critical...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $6,196.98 by the Defense Logistics Agency's Medical Supply Chain on June 27, 2025, for the supply of Gadavist 10 mmol/10 ml vials. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of June 30, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $4,657.14 to AmerisourceBergen Drug Corp for Gadavist 10 mmol/10 ml vials on September 23, 2025, with an ultimate completion date of September 24, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement of pharmaceutical inventory to support federal medical supply requirements. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gadavist 15 mmol/15 ml vials with a ceiling value of $2,101.84. This non-competitive, firm fixed-price delivery order was issued on August 20, 2025, with an ultimate completion date of August 21, 2025. The pharmaceutical product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a competitively awarded delivery order valued at $9,097.83 for Gadavist 10 mmol/10 ml vials from the Defense Logistics Agency's Medical Supply Chain on September 19, 2025, with a completion date of September 22, 2025. This firm fixed-price delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- The Defense Logistics Agency awarded a $3,612.16 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Gadavist 7.5 mmol/7.5 ml vials. The contract, classified as firm fixed price with no set-aside designation, is scheduled for completion by September 15, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a pediatric or diagnostic imaging pharmaceutical product supporting federal medical...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $1,704.90 by the Defense Logistics Agency on June 5, 2025, for the supply of Gadavist 1 mmol/ml bulk vial 30ml. The contract employs firm fixed price pricing and is not set-aside designated, indicating it was competitively awarded. Performance is scheduled for completion by June 6, 2025, with work to be performed at the contractor's Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,175.30 to AmerisourceBergen Drug Corp for the supply of Gadavist 1 mmol/ml bulk vials (30ml). This competitively awarded, firm fixed-price delivery order was issued on September 11, 2025, with an ultimate completion date of September 12, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a small-value...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor, AmerisourceBergen Drug Corporation, a subsidiary of AmerisourceBergen Corporation. The delivery order, valued at $1,573.54, is for the supply of Gadavist 10 mmol/10 ml vial, a pharmaceutical product, to support military treatment programs and facilities. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FDATJDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,501.90 to AmerisourceBergen Drug Corp for Gadavist 10 mmol/10 ml vials on September 22, 2025. This is a firm fixed price delivery order with an ultimate completion date of September 23, 2025, with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor and healthcare solutions provider. This delivery order is a child contract issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Gadavist, a gadolinium-based contrast agent used in medical imaging, represents one of the specialized pharmaceutical products the company provides through this strategic contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 9/22/25 |